LONDON, Mar. 24, 2016 – King & Spalding’s London office advised leading pharmaceutical company GSK on its strategic collaboration with Germany-based Miltenyi Biotec.
The deal will bring together GSK’s expertise in developing cell and gene therapy-based treatments with Miltenyi Biotec’s global leadership in cell processing and related technologies in cell therapy. GSK is building a cell and gene therapy R&D platform to underpin development of novel therapies in oncology and rare diseases – two of its core research areas.
Through the collaboration, Miltenyi Biotec will engage with GSK to integrate greater automation and high-tech processing technology into GSK’s current cell and gene therapy R&D manufacturing capabilities.
King & Spalding’s team on the deal was led by corporate counsel Marcus Young. King & Spalding has previously acted for GSK on the £196 million worldwide agreement to acquire Toctino, the €250 million acquisition of Okairos AG, and, last year, the $190 million (£124 million) acquisition of GlycoVaxyn AG.
About King & Spalding
Celebrating more than 130 years of service, King & Spalding is an international law firm that represents a broad array of clients, including half of the Fortune Global 100, with 900 lawyers in 18 offices in the United States, Europe, the Middle East and Asia. The firm has handled matters in over 160 countries on six continents and is consistently recognized for the results it obtains, uncompromising commitment to quality, and dedication to understanding the business and culture of its clients. More information is available at www.kslaw.com.